This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Böhm, M. Articles by Knorr, A. Search for Related Content PubMed PubMed Citation Articles by Böhm, M. Articles by Knorr, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure

(Hypertension. 1998;31:747-754.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Effects of Angiotensin II Type 1 Receptor Blockade and Angiotensin-Converting Enzyme Inhibition on Cardiac ß-Adrenergic Signal Transduction

Michael Böhm; Oliver Zolk; Markus Flesch; Frank Schiffer; Petra Schnabel; Johannes-Peter Stasch; ; Andreas Knorr

From the Klinik III für Innere Medizin (M.B, O.Z., M.F., F.S., P.S.), Universität zu Köln, Köln, Germany, and Bayer AG (J.P.S., A.K.), Wuppertal, Germany.

Correspondence to Prof Dr Michael Böhm, Klinik III für Innere Medizin, Universität zu Köln, Joseph-Stelzmann-Straße 9, 50924 Köln, Germany. E-mail michael.boehm{at}medizin.uni-koeln.de

Abstract—Inhibition of the renin-angiotensin system has been shown to improve symptoms and prognosis in heart failure. We compared the effects of inhibition of angiotensin-converting enzyme or blockade of angiotensin II type 1 (AT₁) receptors in a model with renin-induced hypertension that is known to exhibit similar changes in sympathetic activation and ß-adrenergic desensitization, as observed in heart failure. Treatment with captopril (100 mg/kg of feed) or the AT₁-antagonist Bay 10–6734 (100 mg/kg of feed) was performed in transgenic rats harboring the mouse renin 2^d gene [TG(mREN2)27]. Neuropeptide Y and angiotensin II levels, adenylyl cyclase activity, ß-adrenergic receptors, G_s, and G_i were investigated. TG(mREN2)27 showed a depletion of myocardial neuropeptide Y stores and an increase in myocardial angiotensin II concentrations. Isoprenaline- and guanylylimidodiphosphate-stimulated adenylyl cyclase activities and ß-adrenergic receptor density were reduced, whereas the catalyst and G_s-function were unchanged. G_i protein and mRNA concentrations were increased. All alterations were normalized by both treatments. Systolic left ventricular pressures, plasma atrial natriuretic peptide, and myocardial steady state atrial natriuretic peptide mRNA concentrations and heart weights were similarly reduced by both treatments. Sympathetic neuroeffector defects are similarly reversed by angiotensin-converting enzyme inhibition or AT₁ antagonism. The data support the concept that pharmacological interventions in the myocardial renin-angiotensin system significantly reverse local sympathetic neuroeffector defects. This could be important for the beneficial effects of these agents.

Key Words: hypertrophy • angiotensin receptor subtypes • catecholamines • adrenoceptors • G proteins

This article has been cited by other articles:

				X. Wang, E. Sentex, H. K. Saini, D. Chapman, and N. S. Dhalla Upregulation of {beta}-adrenergic receptors in heart failure due to volume overload Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H151 - H159. [Abstract] [Full Text] [PDF]

				M. Takahashi, K. Tanonaka, H. Yoshida, R. Oikawa, M. Koshimizu, T. Daicho, T. Toyo-oka, and S. Takeo Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart Cardiovasc Res, February 1, 2005; 65(2): 356 - 365. [Abstract] [Full Text] [PDF]

				I. Kouchi, O. Zolk, F. Jockenhovel, G. Itter, W. Linz, B. Cremers, and M. Bohm Increase in Gi{alpha} Protein Accompanies Progression of Post-Infarction Remodeling in Hypertensive Cardiomyopathy Hypertension, July 1, 2000; 36(1): 42 - 47. [Abstract] [Full Text] [PDF]

				X. Xu, S. J. Rials, Y. Wu, T. Liu, R. A. Marinchak, and P. R. Kowey Effects of Captopril Treatment of Renovascular Hypertension on beta -Adrenergic Modulation of L-Type Ca2+ Current J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 196 - 200. [Abstract] [Full Text]

				A. Warnholtz, G. Nickenig, E. Schulz, R. Macharzina, J. H. Brasen, M. Skatchkov, T. Heitzer, J. P. Stasch, K. K. Griendling, D. G. Harrison, et al. Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis : Evidence for Involvement of the Renin-Angiotensin System Circulation, April 20, 1999; 99(15): 2027 - 2033. [Abstract] [Full Text] [PDF]

				H. P. Brunner-La Rocca, G. Vaddadi, and M. D. Esler Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1163 - 1173. [Abstract] [Full Text] [PDF]

				L. Iouzalen, O. Stepien, and P. Marche Effects of Bay 10-6734 (Embusartan), a New Angiotensin II Type I Receptor Antagonist, on Vascular Smooth Muscle Cell Growth J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 181 - 187. [Abstract] [Full Text]

				M. Bohm, S. Ettelbruck, M. Flesch, W. H van Gilst, A. Knorr, C. Maack, Y. M Pinto, M. Paul, A. C.H Teisman, and O. Zolk {beta}-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy Cardiovasc Res, October 1, 1998; 40(1): 146 - 155. [Abstract] [Full Text] [PDF]